Bactroban Cream (mupirocin calcium) - Drug Summary

GlaxoSmithKline LLC

Related Drug Information

Bactroban Topical (mupirocin)

THERAPEUTIC CLASS

Bacterial protein synthesis inhibitor

DEA CLASS

RX

ADULT DOSAGE & INDICATIONS

Secondarily Infected Traumatic Skin Lesions

Lesions up to 10cm in length or 100cm^2 in area due to *Staphylococcus aureus* and *Streptococcus pyogenes*

Cre:
Apply a small amount to the affected area tid for 10 days; reevaluate if no clinical response w/in 3-5 days

Impetigo

Due to *Staphylococcus aureus* and *Streptococcus pyogenes*

Oint:
Apply a small amount to the affected area tid; reevaluate if no clinical response w/in 3-5 days

PEDIATRIC DOSAGE & INDICATIONS

Secondarily Infected Traumatic Skin Lesions

Lesions up to 10cm in length or 100cm^2 in area due to *Staphylococcus aureus* and *Streptococcus pyogenes*

3 Months-16 Years:
Cre:
Apply a small amount to the affected area tid for 10 days; reevaluate if no clinical response w/in 3-5 days

Impetigo

Due to *Staphylococcus aureus* and *Streptococcus pyogenes*

2 Months-16 Years:
Oint:
Apply a small amount to the affected area tid; reevaluate if no clinical response w/in 3-5 days

ADMINISTRATION

Topical route

May be covered w/ gauze dressing if desired

HOW SUPPLIED

Cre: 2% [15g, 30g]; Oint: 2% [22g]

WARNINGS/PRECAUTIONS

Avoid contact w/ eyes; rinse well w/ water in case of accidental contact. D/C and institute appropriate

alternative therapy if sensitization or severe local irritation occurs. *Clostridium difficile*-associated diarrhea (CDAD) reported; may need to d/c if CDAD is suspected/confirmed. Prolonged use may result in overgrowth of nonsusceptible organism, including fungi. Not for use on mucosal surfaces. (Oint) Contains polyethylene glycol; avoid use in conditions where absorption of large quantities is possible, especially if there is evidence of moderate or severe renal impairment. Avoid use w/ IV cannulae or at central IV sites; may promote fungal infections and antimicrobial resistance.

ADVERSE REACTIONS

Systemic allergic reactions, rash, nausea, burning at application site, dermatitis, dry skin. (Cre) Headache, pruritus. (Oint) Stinging, pain, itching.

PREGNANCY AND LACTATION

Category B, caution in nursing.

MECHANISM OF ACTION

Bacterial protein synthesis inhibitor; inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase.

PHARMACOKINETICS

Absorption: (Cre) Minimal skin absorption. **Distribution:** Plasma protein binding (>97%). **Metabolism:** Rapid once in systemic circulation. **Elimination:** Urine; (IV) $T_{1/2}$=20-40 min.

ASSESSMENT

Assess for hypersensitivity to the drug and pregnancy/nursing status.

MONITORING

Monitor for sensitization, severe local irritation, CDAD, and other adverse reactions.

PATIENT COUNSELING

Instruct to use only ud. Inform that medication is for external use only. Instruct to avoid contact w/ eyes; advise to rinse thoroughly w/ water if therapy gets in or near the eyes. Counsel that treated area can be covered w/ a gauze dressing if desired. Advise to d/c medication and contact physician if irritation, severe itching, or rash occurs. Instruct to notify physician if no improvement is seen in 3-5 days.

STORAGE

(Cre) At or below 25°C (77°F). Do not freeze. (Oint) 20-25°C (68-77°F).

Back to top